AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol (July 15, 2004). doi:10.1152/ajpregu.00339.2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/5/R1116    most recent
00339.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berthiaume, M.
Right arrow Articles by Deshaies, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berthiaume, M.
Right arrow Articles by Deshaies, Y.
Submitted on May 25, 2004
Accepted on July 8, 2004

Actions of PPAR{gamma} agonism on adipose tissue remodeling, insulin sensitivity and lipemia in absence of glucocorticoids

Magalie Berthiaume1, Henrike Sell1, Josee Lalonde1, Yves Gelinas1, Andre Tchernof2, Denis Richard1, and Yves Deshaies1*

1 Department of Anatomy and Physiology, Laval University, Quebec, Quebec, Canada
2 CHUL Medical Research Center, Laval University, Quebec, Quebec, Canada

* To whom correspondence should be addressed. E-mail: yves.deshaies{at}phs.ulaval.ca.

Peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) agonists improve insulin sensitivity and lipemia partly through enhancing adipose tissue proliferation and capacity for lipid retention. The agonists also reduce local adipose glucocorticoid production, which may in turn contribute to their metabolic actions. This study assessed the effects of a PPAR{gamma} agonist in absence of glucocorticoids (adrenalectomy, ADX). Intact, ADX, and intact pair-fed (PF) rats were treated with the PPAR{gamma} agonist rosiglitazone (RSG) for 2 weeks. RSG increased inguinal (subcutaneous) white (50%) and brown adipose tissue (6-fold) weight, but not that of retroperitoneal (visceral) white adipose. ADX, but not PF, reduced fat accretion in both inguinal and retroperitoneal adipose depots, but did not affect brown adipose mass. RSG no longer increased inguinal weight in ADX and PF rats, but increased brown adipose mass, albeit less so than in intact rats. RSG increased cell proliferation in white (3-fold) and brown adipose (6-fold), as assessed microscopically and by total DNA, an effect that was attenuated but not abrogated by ADX. RSG reduced the expression of the glucocorticoid-activating enzyme 11{beta}HSD1 in all adipose depots. RSG improved insulin sensitivity (reduction in fasting insulin and HOMA-IR, both -50%) and triacylglycerolemia (-75%) regardless of the glucocorticoid status, these effects being fully additive to those of ADX and PF. In conclusion, RSG partially retained its ability to induce white and brown adipose cell proliferation and brown adipose fat accretion, and further improved insulin sensitivity and lipemia in ADX rats, such effects being therefore independent from the PPAR{gamma}-mediated modulation of glucocorticoids.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Petrovic, I. G. Shabalina, J. A. Timmons, B. Cannon, and J. Nedergaard
Thermogenically competent nonadrenergic recruitment in brown preadipocytes by a PPAR{gamma} agonist
Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E287 - E296.
[Abstract] [Full Text] [PDF]

Home page
 J ANIM SCIHome page
G. J. Hausman, S. P. Poulos, T. D. Pringle, and M. J. Azain
The influence of thiazolidinediones on adipogenesis in vitro and in vivo: Potential modifiers of intramuscular adipose tissue deposition in meat animals
J Anim Sci, April 1, 2008; 86(14_suppl): E236 - E243.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. Roberge, A. C. Carpentier, M.-F. Langlois, J.-P. Baillargeon, J.-L. Ardilouze, P. Maheux, and N. Gallo-Payet
Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity
Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1465 - E1478.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Laplante, W. T. Festuccia, G. Soucy, Y. Gelinas, J. Lalonde, and Y. Deshaies
Involvement of adipose tissues in the early hypolipidemic action of PPAR{gamma} agonism in the rat
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1408 - R1417.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. Nakano, Y. Inada, H. Masuzaki, T. Tanaka, S. Yasue, T. Ishii, N. Arai, K. Ebihara, K. Hosoda, K. Maruyama, et al.
Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes
Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1213 - E1222.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
P. B. Persson
From clinical insights to new therapies
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R124 - R125.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.